Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | GAA | P10253 | 5/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ALPL | P05186 | 1/20 | 0.45 |
| ▸ | ALPI | P09923 | 1/20 | 0.45 |
| ▸ | ALPG | P10696 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2992234 | 0.73 | HPGD (0.76) | HPGDSMN1; SMN2ALDH1A1GAANPC1 | |
| SCHEMBL28655711 | 0.70 | GAA (0.62) | HPGDSMN1; SMN2ALDH1A1GAANPC1 | |
| SCHEMBL2989424 | 0.67 | ALDH1A1 (0.71) | HPGDSMN1; SMN2ALDH1A1GAAKMT2A | |
| SCHEMBL30825401 | 0.66 | ALDH1A1 (0.67) | HPGDSMN1; SMN2ALDH1A1GAANPC1 | |
| SCHEMBL28660387 | 0.65 | PTGS2 (0.61) | HPGDSMN1; SMN2ALDH1A1GAANPC1 | |
| SCHEMBL28640185 | 0.65 | SMN1; SMN2 (0.61) | HPGDSMN1; SMN2ALDH1A1GAANPC1 | |
| SCHEMBL15103340 | 0.65 | SMN1; SMN2 (0.61) | HPGDSMN1; SMN2ALDH1A1GAANPC1 | |
| SCHEMBL8372435 | 0.63 | POLB (0.78) | HPGDSMN1; SMN2ALDH1A1GAANPC1 | |
| SCHEMBL11013579 | 0.63 | GAA (0.52) | HPGDALDH1A1GAANPC1RAB9A | |
| SCHEMBL3456445 | 0.63 | ALDH1A1 (0.73) | HPGDSMN1; SMN2ALDH1A1GAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197658-A1 | PHARMACEUTICAL USE OF FUSED 1,2,4-TRIAZOLES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-08-05 | — | — | US | disclosed |
| US-7723323-B2 | Pharmaceutical use of fused 1,2,4-triazoles | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-05-25 | — | — | US | disclosed |
| EP-1615647-B1 | PHARMACEUTICAL USE OF FUSED 1,2,4-TRIAZOLES | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20080153807-A1 | Pharmaceutical Use of Fused 1,2,4-Triazoles | NOVO NORDISK A/S (DK) | 2008-06-26 | — | — | US | disclosed |
| US-7358238-B2 | Pharmaceutical use of fused 1,2,4-triazoles | NOVO NORDISK A/S (DK) | 2008-04-15 | — | — | US | disclosed |
| EP-1785424-A2 | Fused 1,2,4-triazoles and pharmaceutical uses thereof | NOVO NORDISK A/S (DK) | 2007-05-16 | — | — | EP | disclosed |
| US-20060106008-A1 | Pharmaceutical use of fused 1,2,4-triazoles | NOVO NORDISK A/S (DK) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106008-A1 | Pharmaceutical use of fused 1,2,4-triazoles | HSD3B1, HSD11B1, HSD11B2 | HPGD 63/4885SMN1; SMN2 4244/4885ALDH1A1 166/4885 |
| US-20080153807-A1 | Pharmaceutical Use of Fused 1,2,4-Triazoles | HSD3B1, HSD11B1, HSD11B2 | HPGD 63/4885SMN1; SMN2 4244/4885ALDH1A1 166/4885 |
| US-20100197658-A1 | PHARMACEUTICAL USE OF FUSED 1,2,4-TRIAZOLES | HSD3B1, HSD11B2, HSD3B2 | HPGD 71/4885SMN1; SMN2 3886/4885ALDH1A1 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.